Genetronics starts trials of cancer drug delivery:
This article was originally published in Clinica
Executive Summary
Trials of Genetronics' electric field-based drug delivery system have begun at nine US centres to test the effectiveness of the technique on difficult-to-treat head and neck cancers. The company, from San Diego California has developed the electroporation therapy that creates temporary pores in cells using electric fields into which drugs can enter. The Phase II trial will follow 25 patients and further sites will join the study. Patients in France and Canada are also being treated for head and neck cancers.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.